For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
According to our LPI (LP Information) latest study, the global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Biologics and Biosimilars. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Biologics and Biosimilars market.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
Key Features:
The report on Biologics and Biosimilars market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Biologics and Biosimilars market. It may include historical data, market Segmentation by Type (e.g., Monoclonal Antibodies, Interferon), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Biologics and Biosimilars market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Biologics and Biosimilars market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Biologics and Biosimilars industry. This include advancements in Biologics and Biosimilars technology, Biologics and Biosimilars new entrants, Biologics and Biosimilars new investment, and other innovations that are shaping the future of Biologics and Biosimilars.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Biologics and Biosimilars market. It includes factors influencing customer ' purchasing decisions, preferences for Biologics and Biosimilars product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Biologics and Biosimilars market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Biologics and Biosimilars market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Biologics and Biosimilars market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Biologics and Biosimilars industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Biologics and Biosimilars market.
Market Segmentation:
Biologics and Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Monoclonal Antibodies
- Interferon
- Insulin
- Vaccines
- Others
Segmentation by application
- Hospital
- Retail Pharmacy
- Other
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Roche
- Amgen
- AbbVie
- Sanofi
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- Biogen
- Celltrion
- Sobi
- 3SBIO
- Changchun High Tech
- Kanghong Pharma
- Innovent Biologics
- Gan&Lee
- Tonghua Dongbao
- United Laboratory